Mirapex

Basic Mirapex information

• INN (international nonproprietary name): Pramipexole.
• Brand names available in the United Kingdom: Mirapexin and generic pramipexole, tablets available in 0.088 mg, 0.18 mg and 0.7 mg strengths, plus extended‑release (ER) formulations; typical pack size 30 tablets.
• ATC code: N04BC05.
• Forms and strengths: Immediate‑release tablets in strengths including 0.088 mg, 0.125 mg, 0.18 mg, 0.25 mg, 0.35 mg, 0.5 mg, 0.7 mg, 0.75 mg, 1 mg, 1.05 mg and 1.5 mg; extended‑release tablets in 0.375 mg, 0.75 mg, 1.5 mg, 2.25 mg, 3 mg, 3.75 mg and 4.5 mg.
• Manufacturers in the United Kingdom: Boehringer Ingelheim (originator), with generics supplied by Teva, Accord Healthcare, Sandoz, Stada, Zentiva, Mylan and Krka.
• Registration status in the United Kingdom: Mirapexin is available in the United Kingdom and pramipexole is listed as prescription only.
• OTC / Rx classification: Prescription only (Rx).

Legal status and availability in the UK

In our online pharmacy, Mirapex is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

What do patients on the NHS report after starting pramipexole?

Pramipexole improves bradykinesia and tremor when used as first‑line treatment in early Parkinson’s disease, and reduces off‑time when added to levodopa.

Extended‑release dosing gives smoother plasma exposure and allows once‑daily dosing, which can help adherence.

Common challenges include dose‑related nausea during titration and daytime somnolence that can affect driving ability.

• Patient challenge: nausea during upward titration.
• Patient challenge: daytime drowsiness impacting driving and work.
• Patient challenge: concern about changes in mood or impulsive behaviour.
• Patient challenge: difficulty with dose timing when on IR three‑times‑daily schedules.

Indications and expanded uses

Which conditions is pramipexole licensed for in the UK?

Approved uses

Parkinson’s disease and restless legs syndrome (RLS).

Common NHS practice

Monotherapy in early Parkinson’s and adjunctive therapy to reduce levodopa‑related off‑time.

Off‑label use

Very limited; occasionally tried in specialist centres for atypical parkinsonian features under close supervision.

Composition and brand landscape

What is the active ingredient and which brands are available in the UK?

The active substance is pramipexole (INN: Pramipexole).

In the United Kingdom the principal brand name is Mirapexin, with multiple generics.

• Major manufacturers: Boehringer Ingelheim (originator), Teva, Accord Healthcare, Sandoz, Stada, Zentiva, Mylan, Krka.
• Classification: prescription only (Rx) in the UK.

Contraindications and special precautions

Who should be screened carefully before starting pramipexole?

• Absolute contraindication: known hypersensitivity to pramipexole or any excipient.
• Precaution: severe renal impairment requires dose reduction and slower titration.
• Precaution: older patients need lower starting doses and careful escalation due to renal decline and increased sensitivity.
• Precaution: a personal or family history of psychotic disorders or impulse‑control disorders is a relative contraindication.
• Precaution: history of low blood pressure or syncope requires orthostatic monitoring.
• Pregnancy/lactation: use only if benefits outweigh risks.
• Driving/work safety: advise against driving if affected by somnolence or sudden sleep attacks and counsel actively during pharmacy consultations.

Dosage guidelines

How is pramipexole started and adjusted in UK practice?

Doses below are expressed as pramipexole salt; in UK product information 0.125 mg of salt corresponds to 0.088 mg of pramipexole base.

• Titration steps for special populations: start lower and walk up more slowly in the elderly and in renal impairment.
• Missed dose advice: take as soon as remembered unless the next dose is due; do not double the dose.
• Overdose warning: supportive care required for confusion, severe hypotension, dyskinesia or hallucinations and urgent medical attention is necessary.

Interactions overview

Which medicines and habits increase risks with pramipexole?

• CNS depressants: concomitant opioids, benzodiazepines or alcohol can increase somnolence and the risk of sudden sleep episodes.
• Dopamine antagonists: antipsychotics that block dopamine receptors may reduce clinical efficacy.
• Antihypertensives and diuretics: combined use has been reported to exacerbate orthostatic hypotension.

Clinicians are encouraged to report suspected interactions and adverse events via the MHRA Yellow Card scheme.

Comparable medicines and prescribing preferences

What are the common alternatives on the NHS and how do they compare?

Other dopamine agonists available on the NHS include ropinirole and the rotigotine transdermal patch, and levodopa remains the standard for symptomatic control in many patients.

• Choice factors: age, renal function, psychiatric history and preference for once‑daily dosing inform selection.
• Prescribing preference: pramipexole is regularly used as a first‑line dopamine agonist in early Parkinson’s where appropriate.

Frequently asked questions

1. Will pramipexole make me sleepy? Somnolence and sudden sleep episodes are reported; avoid driving if affected and report this to the prescribing clinician.
2. What if I miss a dose? Take the missed dose as soon as remembered unless the next dose is due; do not double the dose.
3. How quickly will it work? Motor benefits can be apparent within days, but safe titration typically takes weeks; RLS relief may be noticed quickly after initial doses.
4. Can it cause gambling or sexual urges? Yes, impulse‑control disorders such as gambling or hypersexuality are recognised risks and should be reported immediately.

• When to contact NHS 111 or GP: severe hallucinations, fainting, sudden uncontrollable sleep episodes or concerning behavioural changes.
• Report side effects: patients are encouraged to use the MHRA Yellow Card service to report suspected adverse reactions.

Guidelines for proper use

What should pharmacists and prescribers tell patients starting pramipexole?

• Confirm the indication (Parkinson’s disease or RLS) and review recent renal function and psychiatric history before initiating therapy.
• Explain the titration schedule using the licensed initiation and maximum doses and provide a written dosing plan and symptom diary.
• Warn explicitly about somnolence, sudden sleep attacks and impulse‑control symptoms and advise avoiding driving if symptomatic.
• Recommend ER once‑daily formulations when adherence is a concern and supply clear missed‑dose instructions.
• Storage advice: keep at room temperature between 15–30°C in the original packaging away from moisture and light.
• Follow‑up: encourage neurology nurse follow‑up and advise patients to report side effects via the MHRA Yellow Card scheme and to contact NHS 111 for urgent problems.

Delivery across the United Kingdom